OROCAL Safety Questions, OROCAL Answers
More Here>>Side Effects - FDA Reports 2006-2008
Medications A-Z: A B C D E F G H I J K L M N O P Q R S T U V W X Y ZWelcome! Patientsville.com provides unique information about OROCAL. Our extensive database of OROCAL adverse events and OROCAL warnings is updated regularly. If you have questions, you can post them to one of our health experts or ask others in our broad patient community.
>> Announcements
Check out our Hospital and Home Care Quality Reports.
Ask Our Health Experts about OROCAL
OROCAL Safety Reports
Total OROCAL reports: 4.OROCAL FDA safety alerts: No.
Reported hospitalizations: 4.
Take OROCAL Side Effects Survey or Share Your OROCAL Story. Read More Here.
Consumer or non-health professional from FRANCE reported OROCAL problem on Feb 26, 2007. Female patient, 80 years of age, weighting 99.21 lb, was diagnosed with essential hypertension and was treated with OROCAL. After drug was administered, patient experienced the following problems/side effects: anaemia, blood calcium decreased, blood creatine phosphokinase increased, blood creatinine increased, blood potassium decreased, carbon dioxide decreased, confusional state, creatinine renal clearance decreased, dehydration. OROCAL dosage: unknown. During the same period patient was treated with KARDEGIC, IRBESARTAN, STILNOX, VICTAN, VOLTAREN. Patient was hospitalized. Patient recovered.
OROCAL problem was reported by a Consumer or non-health professional from FRANCE on Apr 18, 2007. Female patient, 80 years of age, weighting 99.21 lb, was diagnosed with essential hypertension and was treated with OROCAL. After drug was administered, patient experienced the following problems/side effects: anaemia, blood calcium decreased, blood creatine phosphokinase increased, blood creatinine increased, blood potassium decreased, carbon dioxide decreased, confusional state, creatinine renal clearance decreased, dehydration. OROCAL dosage: unknown. During the same period patient was treated with KARDEGIC, IRBESARTAN, STILNOX, VICTAN, VOLTAREN. Patient was hospitalized. Patient recovered.
Consumer or non-health professional from FRANCE reported OROCAL problem on Apr 18, 2007. Female patient, 80 years of age, weighting 99.21 lb, was diagnosed with essential hypertension and was treated with OROCAL. After drug was administered, patient experienced the following problems/side effects: anaemia, blood calcium decreased, blood creatine phosphokinase increased, blood creatinine increased, blood potassium decreased, carbon dioxide decreased, confusional state, creatinine renal clearance decreased, dehydration. OROCAL dosage: unknown. During the same period patient was treated with KARDEGIC, IRBESARTAN, STILNOX, VICTAN, VOLTAREN. Patient was hospitalized. Patient recovered.
OROCAL problem was reported by a Health Professional from FRANCE on May 18, 2006. Female patient, 73 years of age, weighting 110.2 lb, was treated with OROCAL. After drug was administered, patient experienced the following problems/side effects: diarrhoea, renal failure acute, vomiting. OROCAL dosage: unknown. During the same period patient was treated with LEXOMIL, ATHYMIL, KALEORID, OMEPRAZOLE, SOLUPRED, CARDENSIEL, ZOCOR, DOXYCYCLINE. Patient was hospitalized. Patient recovered.